Skip to content
Finance Investment, Medical Health Aged Care

Medicinal cannabis company Little Green Pharma (ASX:LGP) records record quarterly revenue and cash receipts

Little Green Pharma 3 mins read

RECORD REVENUE AND CASH RECEIPTS FOR QUARTER AND FINANCIAL YEAR,

POSITIVE OPERATING CASHFLOW FOR FY24 OF $0.5 MILLION

 

Highlights 

  • Record quarterly cash receipts of $8.1 million, up over 50% on previous quarter and over 20% on previous corresponding period
  • Record quarterly revenue of $7.3 million (unaudited), up 34% on previous quarter and over36% on previous corresponding period
  • Record revenue of $25.6million (unaudited) for FY24, up nearly 30% on previous financial year resulting in positive operating cashflow of $0.5million for financial year
  • Cannabis legalised in Germany with its removal from the Narcotics List
  • Cash in bank of $5.0 million at 31 March 2024 up from $3.7 million at 31 December 2023

To view a copy of the company's Quarterly Activities Report lease click here

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

 


About us:

About Little Green Pharma Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution. The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains. Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets. The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems. For more information about Little Green Pharma go to: www.littlegreenpharma.comAbout Little Green PharmaLittle Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.For more information about Little Green Pharma go to: www.littlegreenpharma.comAbout Little Green PharmaLittle Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.For more information about Little Green Pharma go to: www.littlegreenpharma.com


Contact details:

David Tasker 

Chapter One Advisots

E: dtasker@chapteroneadvisors.com.au 

M: 0433 112 936

Media

More from this category

  • Medical Health Aged Care
  • 20/09/2024
  • 02:41
Neuraptive Therapeutics Inc.

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting

– Interim 24-week data from the NEUROFUSE study highlights the safety and efficacy of NTX-001 for peripheral nerve injuries. CHESTERBROOK, Pa.–BUSINESS WIRE– Neuraptive Therapeutics…

  • Contains:
  • Finance Investment
  • 20/09/2024
  • 01:40
EBC Financial Group

EBC Bags BrokersView Best Trading Experience Award, Strengthening Global Leadership

SINGAPORE, Sept. 19, 2024 (GLOBE NEWSWIRE) -- At the BrokersView Award Ceremony in Vietnam in September 2024, EBC Financial Group (EBC) was awarded the “Best Trading Experience” Award, once again solidifying its position as a world-class leader in the financial industry specialising in forex, CFDs, and stocks. The latest award recognised EBC’s commitment to facilitating the most robust trading conditions and delivering an exceptional trading experience.Although the global forex trading market is growing at a rapid pace and is expected to surpass US$10 trillion by 2028 (Source: Yahoo Finance), participation in this increasingly popular financial planning tool is marred by…

  • Medical Health Aged Care
  • 19/09/2024
  • 22:11
Takeda Pharmaceutical Company Limited

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

− Presentations Include New Data from the TAK-861-2001 Phase 2b Trial in Narcolepsy Type 1 Highlighting Impact on Daily Functioning Including Cognition and Sleep…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.